Organisation paid for research Program year 2025 Source: CMS Open Payments

Children's Healthcare of Atlanta

Neither a doctor nor a teaching hospital

Research payments

$1,597,506

308 payments

Through program year 2025, Children's Healthcare of Atlanta is reported as receiving $1,597,506 in research payments, across 308 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$545,802	154
2024	Research	$254,388	54
2023	Research	$148,585	24
2022	Research	$178,294	18
2021	Research	$206,420	34
2020	Research	$186,336	10
2019	Research	$77,683	14

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $333,253 10 payments
DiaSorin Molecular LLC $319,865 2 payments
Adaptive Biotechnologies Corporation $136,200 162 payments
Allergan Inc. $125,212 37 payments
Mirum Pharmaceuticals, Inc. $118,394 14 payments
Abbott Laboratories $117,450 28 payments
Moderna TX, Inc. $110,240 11 payments
Zealand Pharma A/S $94,571 3 payments
Merck Sharp & Dohme Corporation $75,945 2 payments
AbbVie, Inc. $73,151 17 payments

Studies the money was for Research payments · program years 2019–2025

NES Flu A/B (Project DD20-012) $202,995 1 payment
Phase III VTE Prev with Children with ALL $172,406 1 payment
DSM Starfish (DSM-DD23-003) $116,870 1 payment
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age $110,240 11 payments
Car-Cure $103,800 116 payments
Zp4207-21052 $94,571 3 payments
9400530000 BMS ACCL1333 - COG - BMS- ACCL1333 / Apixaban $81,782 1 payment
A Multicenter, Open-label, Phase 2 Extension Trial to Study the Long-term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated with Miransertib in Other Studies $75,945 2 payments
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) $73,523 16 payments
Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai (EMBARK) $66,107 8 payments

What the money was spent on Research payments · program years 2019–2025

Overhead $94,571 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.